Study Results
Results available
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
COMPLETED
Clinical Phase
PHASE2
Total Enrollment
160 participants
Study Classification
INTERVENTIONAL
Study Start Date
2014-10-31
Study Completion Date
2020-07-22
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The purpose of this research study is to learn if the medication Memantine Hydrochloride (the study medication) can help adolescents and young adults with Down syndrome. Dr. Alberto Costa and his research team want to see if a 16-week treatment with this medication can improve the participant's ability to learn and remember things. In this study, memantine hydrochloride will be used. Thus, the researchers want to learn whether the study drug can help improve memory in young adults with Down syndrome. To test the effect of the study medicine, half of the people in the study will receive the study medicine and half will receive a placebo (an inactive substance). Memantine is an approved medication to treat memory and thinking problems in persons with Alzheimer disease. However, little is known about the effect of this medication in persons with Down syndrome and it has not been approved for use in persons with Down syndrome.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Efficacy and Safety of Memantine Hydrochloride in Enhancing the Cognitive Abilities of Young Adults With Down Syndrome
NCT01112683
Down Syndrome
COMPLETED
PHASE4
Memantine and Down's Syndrome
NCT00240760
Down's Syndrome
Dementia
Learning Disabilities
UNKNOWN
NA
Down Syndrome Clinical Trials - Study of Alzheimer's Disease in Down Syndrome
NCT04149197
Alzheimer's Disease in Down Syndrome
TERMINATED
Amyloid Lowering for Alzheimer's in Down's With Donanemab Investigation
NCT06911944
Down Syndrome (DS)
Down Syndrome (Trisomy 21)
Alzheimer Disease
+1 more
NOT_YET_RECRUITING
PHASE4
Effect of Memantine on Cognitive Impairment in Patients With Epilepsy
NCT04417543
Epilepsy
COMPLETED
PHASE1
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
This study seeks to investigate if the medication Memantine Hydrochloride can help young adults with Down syndrome. Two hundred persons with Down syndrome from both genders and between 15 and 32 years of age will be recruited from two sites: Cleveland, OH, USA and São Paulo, SP, Brazil. Participants will be assigned randomly to either a placebo group or a group taking the active medication with a 50% probability of being on either group. Neither the participants nor the investigators will know who will be taking the study medication and who will be taking the placebo during the study. Only the investigational pharmacist will have access to this information.
Up to 60 people with Down syndrome of the recruited study participants will take part on an optional magnetic resonance imaging (MRI) study. This investigation is aimed at helping to make the EEG study more precise and to find out whether the study medication has any significant effect on the structure of the brain.
Additionally, we will recruit a control group of 60 age- and gender-matched participants without Down syndrome. The goal is to investigate how different groups of people activate their brains when they hear or see something, and if he can use high-density EEG and MRI to see how this study medication works in persons with Down syndrome. In other words, this additional control group should help us ascertain which parts of the test results are due to a person having Down syndrome and which ones are not. Persons without Down syndrome will only come for one EEG visit and one MRI visit, and not be asked to take the study medication.
The visits for the participants with Down syndrome will be as follows:
Screening visit (approximately 2-hour long). The subject will be asked about his/her health, medical history, social background, and work background, as well as some simple questions to determine performance on tests of memory and function that are part of this study. Informed consent and assent will be obtained in this visit. At the end of this visit, an EEG machine will be used to access brain responses to different auditory and visual stimuli. Some will be asked if they would be willing to have an MRI performed, but this portion is not imperative.
A urine sample will be collected and used to obtain cells that will be kept frozen for potential future studies. If the date of the screening visit is not convenient, this sample can be collected during any of the next five visits.
Visit 1 (approximately 1 hour). Pulse, blood pressure, and an electrocardiogram (ECG) will be taken. At the end of the visit, urine and blood samples will be taken. Pregnancy will also be checked.
Visit 2 (2-3 hours). Tests of memory, learning, and reasoning skills will be conducted before the start of the study medicine or placebo. At the end of this visit, a 60-day supply of either the study medicine or the placebo will be given. This will need to be taken for 16 weeks.
Visit 3 (approximately 30 minutes). Eight weeks after the beginning of the treatment, the participant will return to assess how she/he is doing under the treatment. Pulse, blood pressure, a physical exam, and pregnancy will be checked. At this visit, another supply of study medicine will be given.
Visit 4 (2-3 hours). Sixteen weeks after starting the medicine, the participant will take a second series of tests in learning, memory, and reasoning skills to find out whether there were any changes in these skills.
Visit 5 (approximately 1 hour). In the 16th or 17th week after starting the medicine, the participant will meet one more time with the doctor from visits 1 and 3. Vital signs, a physical exam, and an ECG will be taken, as well as a blood sample to ensure nothing has changed with the participant's general health. For women, a pregnancy test will be performed.
If for some reason the subject withdraws from this study prior to Visit 5, he/she will be asked to return to the clinic for a "Treatment Discontinuation Visit." In addition, if the participant discontinues the medication prior to the end of the study, he/she will be asked to complete a "Retrieved Dropout Visit" on the date that should have represented Visit 5. Study medication will not be provided beyond the study period.
Up to 60 people with Down syndrome of the recruited study participants will take part on an optional magnetic resonance imaging (MRI) study. This investigation is aimed at helping to make the EEG study more precise and to find out whether the study medication has any significant effect on the structure of the brain.
Additionally, we will recruit a control group of 60 age- and gender-matched participants without Down syndrome. The goal is to investigate how different groups of people activate their brains when they hear or see something, and if he can use high-density EEG and MRI to see how this study medication works in persons with Down syndrome. In other words, this additional control group should help us ascertain which parts of the test results are due to a person having Down syndrome and which ones are not. Persons without Down syndrome will only come for one EEG visit and one MRI visit, and not be asked to take the study medication.
The visits for the participants with Down syndrome will be as follows:
Screening visit (approximately 2-hour long). The subject will be asked about his/her health, medical history, social background, and work background, as well as some simple questions to determine performance on tests of memory and function that are part of this study. Informed consent and assent will be obtained in this visit. At the end of this visit, an EEG machine will be used to access brain responses to different auditory and visual stimuli. Some will be asked if they would be willing to have an MRI performed, but this portion is not imperative.
A urine sample will be collected and used to obtain cells that will be kept frozen for potential future studies. If the date of the screening visit is not convenient, this sample can be collected during any of the next five visits.
Visit 1 (approximately 1 hour). Pulse, blood pressure, and an electrocardiogram (ECG) will be taken. At the end of the visit, urine and blood samples will be taken. Pregnancy will also be checked.
Visit 2 (2-3 hours). Tests of memory, learning, and reasoning skills will be conducted before the start of the study medicine or placebo. At the end of this visit, a 60-day supply of either the study medicine or the placebo will be given. This will need to be taken for 16 weeks.
Visit 3 (approximately 30 minutes). Eight weeks after the beginning of the treatment, the participant will return to assess how she/he is doing under the treatment. Pulse, blood pressure, a physical exam, and pregnancy will be checked. At this visit, another supply of study medicine will be given.
Visit 4 (2-3 hours). Sixteen weeks after starting the medicine, the participant will take a second series of tests in learning, memory, and reasoning skills to find out whether there were any changes in these skills.
Visit 5 (approximately 1 hour). In the 16th or 17th week after starting the medicine, the participant will meet one more time with the doctor from visits 1 and 3. Vital signs, a physical exam, and an ECG will be taken, as well as a blood sample to ensure nothing has changed with the participant's general health. For women, a pregnancy test will be performed.
If for some reason the subject withdraws from this study prior to Visit 5, he/she will be asked to return to the clinic for a "Treatment Discontinuation Visit." In addition, if the participant discontinues the medication prior to the end of the study, he/she will be asked to complete a "Retrieved Dropout Visit" on the date that should have represented Visit 5. Study medication will not be provided beyond the study period.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Down Syndrome
Intellectual Disability
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
RANDOMIZED
Intervention Model
PARALLEL
Primary Study Purpose
TREATMENT
Blinding Strategy
QUADRUPLE
Participants
Caregivers
Investigators
Outcome Assessors
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Placebo
Identically-looking placebo pills to memantine will be dispensed in a 66-day supply (56 days plus 10 extra days) by the study coordinator to participants receiving the placebo at the end of visits 2 and 3.
Group Type
PLACEBO_COMPARATOR
Placebo
Intervention Type
DRUG
Identically looking placebo capsules bid (after a four-week regimen designed to mimic standard dose titration protocol)
Memantine
Memantine will be dispensed in a 66-day supply (56 days plus 10 extra days) by the study coordinator to participants receiving the placebo at the end of visits 2 and 3.
Group Type
EXPERIMENTAL
Memantine
Intervention Type
DRUG
Encapsulated Namenda 10 mg bid (after four-week standard dose titration protocol)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Memantine
Encapsulated Namenda 10 mg bid (after four-week standard dose titration protocol)
Intervention Type
DRUG
Placebo
Identically looking placebo capsules bid (after a four-week regimen designed to mimic standard dose titration protocol)
Intervention Type
DRUG
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Namenda
Inactive Capsules
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Cytogenetically documented Trisomy 21 or Complete Unbalanced Translocation of Chromosome 21. Mosaic Trisomy 21 and partial translocations will be excluded from the study
* No pregnancy by serum testing at screening. Females of child-bearing potential, sexually active must be practicing a reliable method of birth control. Urine pregnancy tests will be done at the 2 follow-up medical visits
* Laboratory findings within normal limits or judged clinically insignificant at baseline
* Vital signs within normal limits for age. Stable, medically treated hypotension will be allowed
* ECG must demonstrate predominately normal sinus rhythm. Minor abnormalities documented as clinically insignificant will be allowed
* Participants and their authorized representatives will provide written informed consent
* Participants who have received any experimental drug for Down syndrome must undergo a washout
* All participants must: Be in general good health as judged by the investigators; Be able to swallow oral medication; Have a reliable caregiver or family member who agrees to accompany participant to all visits, provide information about the participant as required by the protocol, and ensure compliance with the medication schedule; Be sufficiently proficient in English (USA) or Portuguese (Brazil) to reliably complete the study assessments
* Age and gender matching participants without Down syndrome, must be: Males or females without Down syndrome aged-matching (within 3 years) participants with Down syndrome whom they are expected to serve as controls
* No pregnancy by serum testing at screening. Females of child-bearing potential, sexually active must be practicing a reliable method of birth control. Urine pregnancy tests will be done at the 2 follow-up medical visits
* Laboratory findings within normal limits or judged clinically insignificant at baseline
* Vital signs within normal limits for age. Stable, medically treated hypotension will be allowed
* ECG must demonstrate predominately normal sinus rhythm. Minor abnormalities documented as clinically insignificant will be allowed
* Participants and their authorized representatives will provide written informed consent
* Participants who have received any experimental drug for Down syndrome must undergo a washout
* All participants must: Be in general good health as judged by the investigators; Be able to swallow oral medication; Have a reliable caregiver or family member who agrees to accompany participant to all visits, provide information about the participant as required by the protocol, and ensure compliance with the medication schedule; Be sufficiently proficient in English (USA) or Portuguese (Brazil) to reliably complete the study assessments
* Age and gender matching participants without Down syndrome, must be: Males or females without Down syndrome aged-matching (within 3 years) participants with Down syndrome whom they are expected to serve as controls
Exclusion Criteria
* Participant weighing less than 40 kg
* Current psychiatric or neurologic diagnosis other than Down syndrome (e.g., major depressive disorder, schizophrenia, bipolar disorder, autism, Alzheimer disease)
* Current treatment with psychotropic drugs
* Drug or alcohol abuse or dependence
* Significant suicide risk or who would require treatment with electro-convulsive therapy or with psychotropic drugs during the study or who have received treatment with a depot neuroleptic drug within 6 months of entering the study.
* Current or expected (within the next 6 months) hospitalization or residence in a skilled nursing facility (may reside in group homes or other residential settings with no skilled nursing)
* Active or clinically significant conditions affecting absorption, distribution, or metabolism of study drug (e.g. inflammatory bowel disease or celiac disease)
* Significant allergies to or other significant intolerance of memantine therapy, its ingredients, or with contraindications to memantine therapy as stated in the prescribing information
* Participants who are expected to require general anesthetics during the course of the study
* Presence or recent history of seizure disorder (\< 3 years).
* Clinically significant and/or clinically unstable systemic disease. (Those with controlled hypothyroidism must be on a stable dose of medication for at least 3 months prior to screening and have normal serum T-4 and TSH at screening; and those with controlled diabetes mellitus must have an HbA1c of \< 8.0% and a random serum glucose value of \< 170 mg/dl)
* Severe infections or a major surgical operation within 3 months prior to screening
* History of persistent cognitive deficits immediately following head trauma.
* Donation of blood or blood products less that 30 days prior to screening, while participating in the study, or four weeks after completion of the study
* Inability to comply with the protocol or perform the outcomes measures due to significant hearing or visual impairment or other issues judged relevant by the investigators
* Current psychiatric or neurologic diagnosis other than Down syndrome (e.g., major depressive disorder, schizophrenia, bipolar disorder, autism, Alzheimer disease)
* Current treatment with psychotropic drugs
* Drug or alcohol abuse or dependence
* Significant suicide risk or who would require treatment with electro-convulsive therapy or with psychotropic drugs during the study or who have received treatment with a depot neuroleptic drug within 6 months of entering the study.
* Current or expected (within the next 6 months) hospitalization or residence in a skilled nursing facility (may reside in group homes or other residential settings with no skilled nursing)
* Active or clinically significant conditions affecting absorption, distribution, or metabolism of study drug (e.g. inflammatory bowel disease or celiac disease)
* Significant allergies to or other significant intolerance of memantine therapy, its ingredients, or with contraindications to memantine therapy as stated in the prescribing information
* Participants who are expected to require general anesthetics during the course of the study
* Presence or recent history of seizure disorder (\< 3 years).
* Clinically significant and/or clinically unstable systemic disease. (Those with controlled hypothyroidism must be on a stable dose of medication for at least 3 months prior to screening and have normal serum T-4 and TSH at screening; and those with controlled diabetes mellitus must have an HbA1c of \< 8.0% and a random serum glucose value of \< 170 mg/dl)
* Severe infections or a major surgical operation within 3 months prior to screening
* History of persistent cognitive deficits immediately following head trauma.
* Donation of blood or blood products less that 30 days prior to screening, while participating in the study, or four weeks after completion of the study
* Inability to comply with the protocol or perform the outcomes measures due to significant hearing or visual impairment or other issues judged relevant by the investigators
Minimum Eligible Age
15 Years
Maximum Eligible Age
32 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Alana USA Foundation
OTHER
Sponsor Role
collaborator
University Hospitals Cleveland Medical Center
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Alberto C Costa, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
University Hospitals Cleveland Medical Center
Stephen L Ruedrich, MD
Role: STUDY_DIRECTOR
University Hospitals Cleveland Medical Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University Hospitals Case Medical Center
Cleveland, Ohio, United States
Site Status
Sociedade Beneficente Israelita Brasileira Albert Einstein
São Paulo, São Paulo, Brazil
Site Status
Countries
Review the countries where the study has at least one active or historical site.
United States
Brazil
References
Explore related publications, articles, or registry entries linked to this study.
Abbeduto L, Pavetto M, Kesin E, Weissman MD, Karadottir S, O'Brien A, Cawthon S. The linguistic and cognitive profile of Down syndrome: evidence from a comparison with fragile X syndrome. Downs Syndr Res Pract. 2001 Oct;7(1):9-15. doi: 10.3104/reports.109.
Reference Type
BACKGROUND
Bittles AH, Glasson EJ. Clinical, social, and ethical implications of changing life expectancy in Down syndrome. Dev Med Child Neurol. 2004 Apr;46(4):282-6. doi: 10.1017/s0012162204000441. No abstract available.
Reference Type
BACKGROUND
Boada R, Hutaff-Lee C, Schrader A, Weitzenkamp D, Benke TA, Goldson EJ, Costa AC. Antagonism of NMDA receptors as a potential treatment for Down syndrome: a pilot randomized controlled trial. Transl Psychiatry. 2012 Jul 17;2(7):e141. doi: 10.1038/tp.2012.66.
Reference Type
BACKGROUND
Brock J, Jarrold C. Serial order reconstruction in Down syndrome: evidence for a selective deficit in verbal short-term memory. J Child Psychol Psychiatry. 2005 Mar;46(3):304-16. doi: 10.1111/j.1469-7610.2004.00352.x.
Reference Type
BACKGROUND
Carr J. Six weeks to twenty-one years old: a longitudinal study of children with Down's syndrome and their families. Third Jack Tizard memorial lecture. J Child Psychol Psychiatry. 1988 Jul;29(4):407-31. doi: 10.1111/j.1469-7610.1988.tb00734.x.
Reference Type
BACKGROUND
Carr J. Stability and change in cognitive ability over the life span: a comparison of populations with and without Down's syndrome. J Intellect Disabil Res. 2005 Dec;49(Pt 12):915-28. doi: 10.1111/j.1365-2788.2005.00735.x.
Reference Type
BACKGROUND
Chen KH, Reese EA, Kim HW, Rapoport SI, Rao JS. Disturbed neurotransmitter transporter expression in Alzheimer's disease brain. J Alzheimers Dis. 2011;26(4):755-766. doi: 10.3233/JAD-2011-110002.
Reference Type
BACKGROUND
Chez MG, Burton Q, Dowling T, Chang M, Khanna P, Kramer C. Memantine as adjunctive therapy in children diagnosed with autistic spectrum disorders: an observation of initial clinical response and maintenance tolerability. J Child Neurol. 2007 May;22(5):574-9. doi: 10.1177/0883073807302611.
Reference Type
BACKGROUND
Costa AC, Scott-McKean JJ. Prospects for improving brain function in individuals with Down syndrome. CNS Drugs. 2013 Sep;27(9):679-702. doi: 10.1007/s40263-013-0089-3.
Reference Type
BACKGROUND
Costa AC, Scott-McKean JJ, Stasko MR. Acute injections of the NMDA receptor antagonist memantine rescue performance deficits of the Ts65Dn mouse model of Down syndrome on a fear conditioning test. Neuropsychopharmacology. 2008 Jun;33(7):1624-32. doi: 10.1038/sj.npp.1301535. Epub 2007 Aug 15.
Reference Type
BACKGROUND
Danysz W, Parsons CG. Alzheimer's disease, beta-amyloid, glutamate, NMDA receptors and memantine--searching for the connections. Br J Pharmacol. 2012 Sep;167(2):324-52. doi: 10.1111/j.1476-5381.2012.02057.x.
Reference Type
BACKGROUND
Erickson CA, Mullett JE, McDougle CJ. Open-label memantine in fragile X syndrome. J Autism Dev Disord. 2009 Dec;39(12):1629-35. doi: 10.1007/s10803-009-0807-3. Epub 2009 Jul 16.
Reference Type
BACKGROUND
Erickson CA, Posey DJ, Stigler KA, Mullett J, Katschke AR, McDougle CJ. A retrospective study of memantine in children and adolescents with pervasive developmental disorders. Psychopharmacology (Berl). 2007 Mar;191(1):141-7. doi: 10.1007/s00213-006-0518-9. Epub 2006 Oct 3.
Reference Type
BACKGROUND
Fernandez G, Weyerts H, Schrader-Bolsche M, Tendolkar I, Smid HG, Tempelmann C, Hinrichs H, Scheich H, Elger CE, Mangun GR, Heinze HJ. Successful verbal encoding into episodic memory engages the posterior hippocampus: a parametrically analyzed functional magnetic resonance imaging study. J Neurosci. 1998 Mar 1;18(5):1841-7. doi: 10.1523/JNEUROSCI.18-05-01841.1998.
Reference Type
BACKGROUND
Findling RL, McNamara NK, Stansbrey RJ, Maxhimer R, Periclou A, Mann A, Graham SM. A pilot evaluation of the safety, tolerability, pharmacokinetics, and effectiveness of memantine in pediatric patients with attention-deficit/hyperactivity disorder combined type. J Child Adolesc Psychopharmacol. 2007 Feb;17(1):19-33. doi: 10.1089/cap.2006.0044.
Reference Type
BACKGROUND
Francis PT, Palmer AM, Snape M, Wilcock GK. The cholinergic hypothesis of Alzheimer's disease: a review of progress. J Neurol Neurosurg Psychiatry. 1999 Feb;66(2):137-47. doi: 10.1136/jnnp.66.2.137.
Reference Type
BACKGROUND
Hanney M, Prasher V, Williams N, Jones EL, Aarsland D, Corbett A, Lawrence D, Yu LM, Tyrer S, Francis PT, Johnson T, Bullock R, Ballard C; MEADOWS trial researchers. Memantine for dementia in adults older than 40 years with Down's syndrome (MEADOWS): a randomised, double-blind, placebo-controlled trial. Lancet. 2012 Feb 11;379(9815):528-36. doi: 10.1016/S0140-6736(11)61676-0. Epub 2012 Jan 10.
Reference Type
BACKGROUND
Hosenbocus S, Chahal R. Memantine: a review of possible uses in child and adolescent psychiatry. J Can Acad Child Adolesc Psychiatry. 2013 May;22(2):166-71.
Reference Type
BACKGROUND
Hu NW, Ondrejcak T, Rowan MJ. Glutamate receptors in preclinical research on Alzheimer's disease: update on recent advances. Pharmacol Biochem Behav. 2012 Feb;100(4):855-62. doi: 10.1016/j.pbb.2011.04.013. Epub 2011 Apr 22.
Reference Type
BACKGROUND
Jarrold C, Baddeley AD, Hewes AK. Verbal short-term memory deficits in Down syndrome: a consequence of problems in rehearsal? J Child Psychol Psychiatry. 2000 Feb;41(2):233-44.
Reference Type
BACKGROUND
Javitt DC, Steinschneider M, Schroeder CE, Arezzo JC. Role of cortical N-methyl-D-aspartate receptors in auditory sensory memory and mismatch negativity generation: implications for schizophrenia. Proc Natl Acad Sci U S A. 1996 Oct 15;93(21):11962-7. doi: 10.1073/pnas.93.21.11962.
Reference Type
BACKGROUND
Kaindl AM, Degos V, Peineau S, Gouadon E, Chhor V, Loron G, Le Charpentier T, Josserand J, Ali C, Vivien D, Collingridge GL, Lombet A, Issa L, Rene F, Loeffler JP, Kavelaars A, Verney C, Mantz J, Gressens P. Activation of microglial N-methyl-D-aspartate receptors triggers inflammation and neuronal cell death in the developing and mature brain. Ann Neurol. 2012 Oct;72(4):536-49. doi: 10.1002/ana.23626.
Reference Type
BACKGROUND
Kew JN, Kemp JA. Ionotropic and metabotropic glutamate receptor structure and pharmacology. Psychopharmacology (Berl). 2005 Apr;179(1):4-29. doi: 10.1007/s00213-005-2200-z. Epub 2005 Feb 25.
Reference Type
BACKGROUND
Kornhuber J, Kennepohl EM, Bleich S, Wiltfang J, Kraus T, Reulbach U, Meineke I. Memantine pharmacotherapy: a naturalistic study using a population pharmacokinetic approach. Clin Pharmacokinet. 2007;46(7):599-612. doi: 10.2165/00003088-200746070-00005.
Reference Type
BACKGROUND
Korostenskaja M, Nikulin VV, Kicic D, Nikulina AV, Kahkonen S. Effects of NMDA receptor antagonist memantine on mismatch negativity. Brain Res Bull. 2007 May 30;72(4-6):275-83. doi: 10.1016/j.brainresbull.2007.01.007. Epub 2007 Feb 2.
Reference Type
BACKGROUND
Leverenz JB, Raskind MA. Early amyloid deposition in the medial temporal lobe of young Down syndrome patients: a regional quantitative analysis. Exp Neurol. 1998 Apr;150(2):296-304. doi: 10.1006/exnr.1997.6777.
Reference Type
BACKGROUND
Li S, Mallory M, Alford M, Tanaka S, Masliah E. Glutamate transporter alterations in Alzheimer disease are possibly associated with abnormal APP expression. J Neuropathol Exp Neurol. 1997 Aug;56(8):901-11. doi: 10.1097/00005072-199708000-00008.
Reference Type
BACKGROUND
Li S, Hong S, Shepardson NE, Walsh DM, Shankar GM, Selkoe D. Soluble oligomers of amyloid Beta protein facilitate hippocampal long-term depression by disrupting neuronal glutamate uptake. Neuron. 2009 Jun 25;62(6):788-801. doi: 10.1016/j.neuron.2009.05.012.
Reference Type
BACKGROUND
Lieberman DN, Mody I. Regulation of NMDA channel function by endogenous Ca(2+)-dependent phosphatase. Nature. 1994 May 19;369(6477):235-9. doi: 10.1038/369235a0.
Reference Type
BACKGROUND
Lockrow J, Boger H, Bimonte-Nelson H, Granholm AC. Effects of long-term memantine on memory and neuropathology in Ts65Dn mice, a model for Down syndrome. Behav Brain Res. 2011 Aug 10;221(2):610-22. doi: 10.1016/j.bbr.2010.03.036. Epub 2010 Apr 2.
Reference Type
BACKGROUND
Marczynski TJ. GABAergic deafferentation hypothesis of brain aging and Alzheimer's disease; pharmacologic profile of the benzodiazepine antagonist, flumazenil. Rev Neurosci. 1995 Jul-Sep;6(3):221-58. doi: 10.1515/revneuro.1995.6.3.221.
Reference Type
BACKGROUND
Naatanen R. The mismatch negativity: a powerful tool for cognitive neuroscience. Ear Hear. 1995 Feb;16(1):6-18.
Reference Type
BACKGROUND
Naatanen R. Mismatch negativity (MMN) as an index of central auditory system plasticity. Int J Audiol. 2008 Nov;47 Suppl 2:S16-20. doi: 10.1080/14992020802340116.
Reference Type
BACKGROUND
Parker SE, Mai CT, Canfield MA, Rickard R, Wang Y, Meyer RE, Anderson P, Mason CA, Collins JS, Kirby RS, Correa A; National Birth Defects Prevention Network. Updated National Birth Prevalence estimates for selected birth defects in the United States, 2004-2006. Birth Defects Res A Clin Mol Teratol. 2010 Dec;88(12):1008-16. doi: 10.1002/bdra.20735. Epub 2010 Sep 28.
Reference Type
BACKGROUND
Parsons CG, Stoffler A, Danysz W. Memantine: a NMDA receptor antagonist that improves memory by restoration of homeostasis in the glutamatergic system--too little activation is bad, too much is even worse. Neuropharmacology. 2007 Nov;53(6):699-723. doi: 10.1016/j.neuropharm.2007.07.013. Epub 2007 Aug 10.
Reference Type
BACKGROUND
Patterson D, Costa AC. Down syndrome and genetics - a case of linked histories. Nat Rev Genet. 2005 Feb;6(2):137-47. doi: 10.1038/nrg1525. No abstract available.
Reference Type
BACKGROUND
Pennington BF, Moon J, Edgin J, Stedron J, Nadel L. The neuropsychology of Down syndrome: evidence for hippocampal dysfunction. Child Dev. 2003 Jan-Feb;74(1):75-93. doi: 10.1111/1467-8624.00522.
Reference Type
BACKGROUND
Petrides M, Milner B. Deficits on subject-ordered tasks after frontal- and temporal-lobe lesions in man. Neuropsychologia. 1982;20(3):249-62. doi: 10.1016/0028-3932(82)90100-2.
Reference Type
BACKGROUND
Picton TW, Alain C, Otten L, Ritter W, Achim A. Mismatch negativity: different water in the same river. Audiol Neurootol. 2000 May-Aug;5(3-4):111-39. doi: 10.1159/000013875.
Reference Type
BACKGROUND
Roizen NJ, Patterson D. Down's syndrome. Lancet. 2003 Apr 12;361(9365):1281-9. doi: 10.1016/S0140-6736(03)12987-X.
Reference Type
BACKGROUND
Rueda N, Llorens-Martin M, Florez J, Valdizan E, Banerjee P, Trejo JL, Martinez-Cue C. Memantine normalizes several phenotypic features in the Ts65Dn mouse model of Down syndrome. J Alzheimers Dis. 2010;21(1):277-90. doi: 10.3233/JAD-2010-100240.
Reference Type
BACKGROUND
Sani G, Serra G, Kotzalidis GD, Romano S, Tamorri SM, Manfredi G, Caloro M, Telesforo CL, Caltagirone SS, Panaccione I, Simonetti A, Demontis F, Serra G, Girardi P. The role of memantine in the treatment of psychiatric disorders other than the dementias: a review of current preclinical and clinical evidence. CNS Drugs. 2012 Aug 1;26(8):663-90. doi: 10.2165/11634390-000000000-00000.
Reference Type
BACKGROUND
Scott-McKean JJ, Costa AC. Exaggerated NMDA mediated LTD in a mouse model of Down syndrome and pharmacological rescuing by memantine. Learn Mem. 2011 Nov 18;18(12):774-8. doi: 10.1101/lm.024182.111. Print 2011 Dec.
Reference Type
BACKGROUND
Seow D, Gauthier S. Pharmacotherapy of Alzheimer disease. Can J Psychiatry. 2007 Oct;52(10):620-9. doi: 10.1177/070674370705201003.
Reference Type
BACKGROUND
Seung HK, Chapman R. Digit span in individuals with Down syndrome and in typically developing children: temporal aspects. J Speech Lang Hear Res. 2000 Jun;43(3):609-20. doi: 10.1044/jslhr.4303.609.
Reference Type
BACKGROUND
Swainson R, Hodges JR, Galton CJ, Semple J, Michael A, Dunn BD, Iddon JL, Robbins TW, Sahakian BJ. Early detection and differential diagnosis of Alzheimer's disease and depression with neuropsychological tasks. Dement Geriatr Cogn Disord. 2001 Jul-Aug;12(4):265-80. doi: 10.1159/000051269.
Reference Type
BACKGROUND
Tayeb HO, Yang HD, Price BH, Tarazi FI. Pharmacotherapies for Alzheimer's disease: beyond cholinesterase inhibitors. Pharmacol Ther. 2012 Apr;134(1):8-25. doi: 10.1016/j.pharmthera.2011.12.002. Epub 2011 Dec 16.
Reference Type
BACKGROUND
Tikhonravov D, Neuvonen T, Pertovaara A, Savioja K, Ruusuvirta T, Naatanen R, Carlson S. Dose-related effects of memantine on a mismatch negativity-like response in anesthetized rats. Neuroscience. 2010 Jun 2;167(4):1175-82. doi: 10.1016/j.neuroscience.2010.03.014. Epub 2010 Mar 15.
Reference Type
BACKGROUND
Tilleux S, Hermans E. Neuroinflammation and regulation of glial glutamate uptake in neurological disorders. J Neurosci Res. 2007 Aug 1;85(10):2059-70. doi: 10.1002/jnr.21325.
Reference Type
BACKGROUND
Turner S, Alborz A. Academic attainments of children with Down's syndrome: a longitudinal study. Br J Educ Psychol. 2003 Dec;73(Pt 4):563-83. doi: 10.1348/000709903322591244.
Reference Type
BACKGROUND
Turner S, Alborz A, Gayle V. Predictors of academic attainments of young people with Down's syndrome. J Intellect Disabil Res. 2008 May;52(Pt 5):380-92. doi: 10.1111/j.1365-2788.2007.01038.x. Epub 2008 Jan 14.
Reference Type
BACKGROUND
Umbricht D, Schmid L, Koller R, Vollenweider FX, Hell D, Javitt DC. Ketamine-induced deficits in auditory and visual context-dependent processing in healthy volunteers: implications for models of cognitive deficits in schizophrenia. Arch Gen Psychiatry. 2000 Dec;57(12):1139-47. doi: 10.1001/archpsyc.57.12.1139.
Reference Type
BACKGROUND
Vicari S, Marotta L, Carlesimo GA. Verbal short-term memory in Down's syndrome: an articulatory loop deficit? J Intellect Disabil Res. 2004 Feb;48(Pt 2):80-92. doi: 10.1111/j.1365-2788.2004.00478.x.
Reference Type
BACKGROUND
Vicari S, Caselli MC, Gagliardi C, Tonucci F, Volterra V. Language acquisition in special populations: a comparison between Down and Williams syndromes. Neuropsychologia. 2002;40(13):2461-70. doi: 10.1016/s0028-3932(02)00083-0.
Reference Type
BACKGROUND
Zigman W, Schupf N, Haveman M, Silverman W. The epidemiology of Alzheimer disease in intellectual disability: results and recommendations from an international conference. J Intellect Disabil Res. 1997 Feb;41 ( Pt 1):76-80. doi: 10.1111/j.1365-2788.1997.tb00679.x.
Reference Type
BACKGROUND
Zigman WB, Lott IT. Alzheimer's disease in Down syndrome: neurobiology and risk. Ment Retard Dev Disabil Res Rev. 2007;13(3):237-46. doi: 10.1002/mrdd.20163.
Reference Type
BACKGROUND
Costa AC. Alzheimer disease: Treatment of Alzheimer disease in Down syndrome. Nat Rev Neurol. 2012 Mar 13;8(4):182-4. doi: 10.1038/nrneurol.2012.40. No abstract available.
Reference Type
BACKGROUND
Choi DW. Excitotoxic cell death. J Neurobiol. 1992 Nov;23(9):1261-76. doi: 10.1002/neu.480230915.
Reference Type
BACKGROUND
Brandão IM, V. F, R. MR (2012) Prevalence of People with Down Syndrome in Brazil. In: Scientia Plena (www.scientiaplena.org.br).
Reference Type
BACKGROUND
Pueschel SM, Hopmann MR (1993) Speech and language abilities of children with Down syndrome. In: Enhancing children's communication: Research foundations for intervention (Kaisen AP, Gray DB, eds), pp 335-362. London: Brookes.
Reference Type
BACKGROUND
Costa ACS, Brandao AC, Boada R, Barrionuevo VL, Taylor HG, Roth E, Stasko MR, Johnson MW, Assir FF, Roberto MP, Salmona P, Abreu-Silveira G, Bederman I, Prendergast E, Huls A, Abrishamcar S, Mustacchi Z, Scheidemantel T, Roizen NJ, Ruedrich S. Safety, efficacy, and tolerability of memantine for cognitive and adaptive outcome measures in adolescents and young adults with Down syndrome: a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Neurol. 2022 Jan;21(1):31-41. doi: 10.1016/S1474-4422(21)00369-0.
Reference Type
RESULT
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol and Statistical Analysis Plan
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
121971
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
A Study of the Safety and Efficacy of Memantine in Moderate to Severe Alzheimer's Disease
NCT00322153
COMPLETED
PHASE3
Memantine for the Reduction of Cognitive Impairment After Radiation Therapy in Pediatric Patients With Central Nervous System Tumors
NCT04217694
COMPLETED
EARLY_PHASE1
Safety and Efficacy of MEM 1003 Versus Placebo in Patients With Mild to Moderate Alzheimer's Disease
NCT00257673
COMPLETED
PHASE2
NMDA-enhancing Agent for the Treatment of Mild Cognitive Impairment
NCT02239003
COMPLETED
PHASE2
Attenuation of Corticosteroid Induced Hippocampal Changes
NCT01656187
COMPLETED
PHASE4
Evaluating The Efficacy And Safety Of Donepezil Hydrochloride (Aricept) In The Treatment Of The Cognitive Dysfunction Exhibited By Children With Down Syndrome, Aged 11 To 17
NCT00754052
TERMINATED
PHASE3
Effect of Early Memantine Administration on Outcome of Patients With Moderate to Severe Traumatic Brain Injury
NCT05531383
UNKNOWN
NA
Multicenter Evaluation of Memory Remediation After TBI With Donepezil
NCT02255799
COMPLETED
PHASE3
Investigation of Memantine in the Treatment of Memory, Concentration or Attention Problems
NCT01261741
COMPLETED
PHASE2
Efficacy and Safety of Memantine for Parkinson's Disease Dementia (PDD) and Dementia With Lewy Bodies (DLB)
NCT00630500
COMPLETED
PHASE2
Memantine Treatment in Alzheimer's Disease Patients
NCT03168997
UNKNOWN
PHASE4
Evaluating The Safety Of Donepezil Hydrochloride (Aricept) For Up To 1 Year In The Treatment Of The Cognitive Dysfunction Exhibited By Children With Down Syndrome - Follow-Up To A 10-Week, Double-Blind, Placebo-Controlled Trial
NCT00675025
TERMINATED
PHASE2
Safety and Tolerability of Memantine in Moderate to Severe Alzheimer's Disease
NCT00857233
TERMINATED
PHASE3
The Impact of Memantine on Electroconvulsive Therapy (ECT): Will it Improve Response and Protect Against Cognitive Problems?
NCT00988663
WITHDRAWN
NA
The Effect of Memantine on Brain Structure and Chemistry in Alzheimer's Disease Patients
NCT00255086
COMPLETED
PHASE3
Study of Memantine to Treat Huntington's Disease
NCT00652457
COMPLETED
PHASE4
A Study to Assess the Effects of ACI-24.060 in Alzheimer's Disease and in Down Syndrome (ABATE Study)
NCT05462106
RECRUITING
PHASE1/PHASE2
Safety and Efficacy of BMMNCin Patients With Mental Retardation
NCT01908400
UNKNOWN
PHASE1/PHASE2
Methylphenidate for Apathy in Alzheimer's Dementia: A Controlled Study
NCT00495820
COMPLETED
PHASE4
Memantine (10mg BID) for the Frontal and Temporal Subtypes of Frontotemporal Dementia
NCT00545974
COMPLETED
PHASE4
Evaluating The Efficacy And Safety Of Donepezil Hydrochloride (HCl) (Aricept) In Treating Cognitive Dysfunction Exhibited By Children With Down Syndrome
NCT00570128
COMPLETED
PHASE2
The Effect of Memantine on Functional Outcomes and Motor Neuron Degeneration in Amyotrophic Lateral Sclerosis (ALS)
NCT00409721
COMPLETED
PHASE2
Preliminary Efficacy and Safety Study of ST101 in Alzheimer's Disease
NCT00842673
COMPLETED
PHASE2
The PLasma for Alzheimer SymptoM Amelioration (PLASMA) Study
NCT02256306
COMPLETED
NA
Comparison of Once Daily and Twice Daily Dosing on Safety and Tolerability of Memantine in Patients With Alzheimer
NCT02553928
COMPLETED
PHASE4